Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BAGGER, 2 BAGGER AND TRIPLE BAGGER
Price/ Bagger price
Closing in on a double **
No movement - NM
NM HEXO HEXO $0.68 $1.44
NM CVSI CVSI $0.47 $0.84
NM EMHTF Emerald $0.11 $0.22
KSHB KushCo $0.74 $1.08 **
NM GGBXF Green Growth $0.06 $0.12
NM ACB Aurora $0.72 $1.52
NM AGEEF Halo Labs $0.07 $0.14
ITHUF Ianthus $0.64 $0.96 **
NM KHRNF Khiron Life Sciences $0.34 $0.62
NM LHSIF Liberty Health Science $0.29 $0.56
NM MDCL Medicine Man $1.24 $2.48
MMNFF Medmen Enterprises $0.21 $0.36 **
NM NDVAF Indiva $0.14 $0.28
NM CHOOF Choom Holdings $0.06 $0.12
NM NXTTF Namaste Technologies $0.22 $0.42
NM PHVAF Phivida Holdings Inc $0.04 $0.08
PLNHF Planet 13 Holdings $1.01 $1.88 **
PLPRF Plus Products Inc $0.39 $0.66 **
NM SRUTF Sproutly $0.07 $0.14
SNNVF Sunniva Inc $0.12 $0.20 **
NM SPRWF Supreme $0.15 $0.30
TGIFF 1933 Industries Inc $0.08 $0.14 **
NM TGODF Green Organic Dutchman $0.21 $0.44
NM VVCIF VIVO $0.13 $0.26
NM TLLTF TILT Holdings Inc $0.14 $0.28
NM WDDMF WeedMD Inc $0.22 $0.42
Indiva Ltd (QX) (NDVAF)
0.33305 +0.03705 (12.52%)
Looking for low cost runners!!
$TGIF set to rocket
http://thecse.com/en/listings/diversified-industries/friday-night-inc
Yeah, I am not much interested in Falcon. Thanks ...
$FLCN - BUYER BEWARE! NO REVENUE, NO PRODUCTS, SHELL RISK, POSSIBLE INSIDER TRADING.
DESCRIPTION
Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.) is a nutraceutical company developing a range of CBD-based products. The company's mission is to employ best practice science to source, manufacture and package all of its CBD products from within the United States. The company performs farm site visits and manufacturing site visits and sources its products from only the highest quality hemp farms and processors in North America. The company also aims to launch a line of CBD products specially formulated for animals by the end of 2019.
FLCN, low market cap and few shares available for sale
If you like edibles, take a look at Plus Products.
Just wait to buy CROP 22 or 23 U.S.
$ITMC is an interesting option for #cannabis investors - check them out https://www.itoco.net/about.html
Falcon Technologies aka Eco-Growth Strategies Enters Into LOI With Neutrisci To Manufacture Sublingual CBD Products
Signing of definitive agreement expected in early Q2
First orders expected in early Q3
SACRAMENTO, CA / ACCESSWIRE / March 25, 2019 / Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, and Falcon Technologies, Inc. ("Falcon") (FLCN:OTC PINK) are pleased to jointly announce they have entered into a Letter of Intent to create a sublingual CBD tablet.
NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products. Upon the successful completion of a due-diligence period, both companies will work towards signing a definitive agreement in early Q2/2019.
Falcon Chairman and Chief Executive Officer William J. Delgado stated, "NeutriSci International has certain knowledge, technology and IP to create sublingual tablets for the delivery of nutraceuticals and vitamins including CBD, in which these CBD tablets have better absorption rates than other nutraceuticals and vitamins. As we have previously announced, we plan on meeting early core goals including initial product introduction by the end of April 2019."
Mr. Delgado continued, "An integral part of our plan going forward is to have short-term goals as well as long-term goals. Developing a CBD product that has better absorption rates than our competition's products is part of our long-term plan to create a competitive advantage. We believe that NeutriSci has certain technologies that will allow us to meet our internal specifications of a sublingual product which will add to our initial product line. If all goes according to plan, this CBD sublingual tablet will be available for sale by Q3 2019."
Mr. Delgado concluded his comments by saying, "We chose NeutriSci because they already have proven they have the technology we desire, and they have demonstrated an ability to bring products to market which are currently being marketed throughout North America. They are the perfect partner."
Glen Rehman, CEO of NeutriSci International said, "We are pleased at the prospects of offering Falcon an effective delivery method to bring an additional CBD product to the US marketplace. We will be working directly with Falcon to establish a long-term working relationship to develop and launch multiple ground-breaking products and expect revenue from this collaboration in Q3."
About Falcon Technologies
Falcon Technologies, Inc. (a/k/a Eco-Growth Strategies, Inc.) is a nutraceutical company developing a range of CBD-based products. The company's mission is to employ best practice science to source, manufacture and package all of its CBD products from within the United States. The company performs farm site visits and manufacturing site visits and sources its products from only the highest quality hemp farms and processors in North America. The company also aims to launch a line of CBD products specially formulated for animals by the end of 2019.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci's is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy ®, the Company's natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
For more information, please visit: www.neutrisci.com.
William Delgado
djwllc@hotmail.com
775-443-4740
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
SOURCE: Falcon Technologies
View source version on accesswire.com:
https://www.accesswire.com/539947/Falcon-Technologies-aka-Eco-Growth-Strategies-Enters-Into-LOI-With-Neutrisci-To-Manufacture-Sublingual-CBD-Products
CANNABIS DIVISION
Incorporated in its current form in 2015, MCL draws on over 15 years of licensed cannabis cultivation and genetic development
Low-THC hemp food products approved for sale in Australia
Agreement with Algae.Tec (ASX:AEB) – AEB to give MCL 19.9% of its equity for access to seed bank & expertise
Federal Government announces that it will allow export of Australian medicinal Cannabis products
MCL acquires interest in Hemp Hulling Co., completing seed-tocustomer integration of food business
Nov 17
MCL and CannTab sign JV agreement for Australian and Asian market
John Easterling joins MCL board
Nov 17
Dec 17
Jan 18
Jan 18
First 20 Tonnes of Seed secured for sowing in November with legislation approval
Sep 17
MCL engages the services of EndoCro Ltd, an iCAN Israel-Cannabis company for research and development of medicinal Cannabis products
Oct 17
VitaHemp launches its new Hemp Food Seed
Processing plant expansion to be completed for food products division
Feb 18
MCL completes an agreement to sponsor research into Medical Cannabis Treatments for Multiple Sclerosis with the Research and Development Foundation at the Technion Institute, Haifa, Israel under the leadership of Dr. David (Dedi) Meiri and his team
MCL implements Canntab drug development strategy in conjunction with Certara’s Dr Andreas Wallnoefer and Dr Graham Scott to distribute Canntab XR medication in Australia
MCL first to release Australian Hemp Seed Oil gel Capsules
Feb 18
Mar 18
Apr 18
COLES now selling Hemp Products provided by MCL through Red Tractor
Medcan and MCL acquisitions announced. Medcan is licensed by the ODC for medical Cannabis cultivation and production
Medcan obtains Medical Cannabis import/export licence.
Apr 18
Jun 18
Jul 18
4Q 2018
Dr. David (Dedi) Meiri and his team make a ground breaking discovery identifying a cannabinoid that could lead to potential cure for Multiple Sclerosis (MS)
Aug 18
Nov 17
Review of Operations https://hotcopper.com.au/threads/ann-annual-report-to-shareholders.4501731/#post-36232195
Queen Bauxite. NAME CHANGE ALREADY!!!!!!!!
WEED Manufacture Licence Secured
Office of Drug Control Manufacture Licence Secured
Sydney, Oct 10, 2018 AEST (ABN Newswire) - The Board of Queensland Bauxite Limited (ASX:QBL) (or "the company") is pleased to announce that its soon to be wholly owned subsidiary, Medcan Australia, has secured a Medical Cannabis Manufacture Licence under the ODC (Office of Drug Control).
This licence will allow Medcan, subject to individual permit issue, the ability to manufacture its range of products, including but not limited to:
- Dried flower finished products
- Full extract oils
- Tinctures
- Capsules
- Medicinal cannabis products manufactured in Australia under a GMP Licence
- Medicinal cannabis products listed as export-only or registered in the ARTG
- Extracts of cannabis (or cannabis resin) manufactured under a Narcotic Drugs Act 1967 Licence that are not in the final dosage form
- The Contract manufacture of other licenced producers' products
Medcan Australia's CEO, Craig Cochran commented, "We are extremely happy to secure our Manufacture Licence. This is the last ODC (Office of Drug Control) licence required for us to complete our vertically integrated business model".
Medcan has also secured a QLD Health Licence allowing for the storage of Schedule 9 substances, including Cannabis Seeds; and a DAWR Permit (Department of Agriculture and Water Resources Permit) allowing for the importation of plant materials, specifically cannabis seeds.
Medcan currently holds the following valuable ODC, Federal & State licenses:
o ODC Medical Cannabis Cultivation and Production Licence
o ODC Import Licence
o ODC Medical Cannabis Manufacture Licence
o ODC Export Licence
o DAWR (Department of Agriculture and Water Resources) Permit
o QLD Health Licence - Schedule 9 Substances
Pnina Feldman, Executive Chairperson of QBL said, "We are very pleased that Medcan has secured this valuable manufacture licence thus ensuring the continuing development of our Medical Cannabis project in Australia and finally completing the company's second fully vertically integrated business model, in the nutritional and medical Cannabis industries. The Medcan team continue to impress us with their professionalism and expertise, and being one of the only MM companies now in Australia to have secured all these valuable ODC Medical Cannabis licences. We look forward to working together, with our International network of experienced and dedicated team members, who will continue to build on these achievements to create shareholder wealth."
About Queensland Bauxite Ltd
Queensland Bauxite Limited (ASX:QBL) is an Australian listed company focused on the exploration and development of its bauxite tenements in Queensland and New South Wales. The Company's lead project is the South Johnstone Bauxite Deposit in northern Queensland which has rail running through the project area and is approximately 15-24 kilometres from the nearest deep water port. The Company intends to become a bauxite producer with a focus on commencing production at South Johnstone as early as possible. The Company also pursues additional investment opportunities, and has agreed to acquire a 100% shareholding in Medical Cannabis Limited, an Australian leader in the hemp and Cannabis industries, and a 100% shareholding in Medcan Australia Pty Ltd, a company with an ODC cultivation and production License and a DA approved Cannabis production and manufacturing facility.
Contact
Queensland Bauxite Ltd
Tel: +61-2-9291-9000
For further information or any queries please email the Company at:
sfeldman@queenslandbauxite.com.au
Cann Global as re-listed.
Link: ODC MANUFACTURE LICENCE SECURED
Tetra Bio-Pharma’s Dr. Chamberland to Announce Health Canada’s Green Light for the Cannabis vs. Fentanyl Trial
ORLEANS, Ontario, Aug. 08, 2018 (GLOBE NEWSWIRE)
https://web.tmxmoney.com/article.php?newsid=5697905967789387&qm_symbol=TBP
Did you get taken care of?
I will try to wind down this board. There is a general board,
a Canadian board and a U.S. board. This board is unnecessary.
IHUB “Cannabis” discussion boards
Australian Weed!
Canadian Weed!
Cannabis American Companies
Cannabis Canadian and U. S. Priced At $0.75 to $10.00
Cannabis Best Opportunity Stocks $0.10 to $0.75
Cannabis Investment Club (Cannabis stock picker contest)
Cannabis IPO Watch CA and US
Cannabis - smoke, vape, ingest, oil, etc.
ABCCF ABCANN GLOBAL
ABX BARRICK GOLD CO
CDE COEUR MINING INC
CGC CANOPY GROWTH
CRXPF CROP INFRASTRUC
CVSI CV SCIENCES INC
EMHTF EMERALD HEALTH watching closely
GG GOLDCORP INC CO
HYYDF HYDROPOTHECARY
NXTTF NAMASTE TECH
OGRMF ORGANIGRAM
PTOTF PATRIOT ONE TECH
RXMD PROGRESSIVE CARE
SNNVF SUNNIVA INC
SPRWF SUPREME watching closely
TGODF GREEN ORGANIC DUTCHMAN
TLRY TILRAY INC COM
USLV CREDIT SUISSE AG
WDDMF WEEDMD INC watching closely
WPM WHEATON PRECIOUS METALS
Didn’t you sent something on the other board. Are there stocks list you can share. The ones you were saying 10-12
IHUB “Cannabis” discussion boards
Australian Weed!
Canadian Weed!
Cannabis American Companies
Cannabis Canadian and U. S. Priced At $0.75 to $10.00
Cannabis Best Opportunity Stocks $0.10 to $0.75
Cannabis Investment Club (Cannabis stock picker contest)
Cannabis IPO Watch CA and US
Cannabis - smoke, vape, ingest, oil, etc.
Valens Groworks might have bottomed. This is one of the lowest market caps out of all Canadian cannabis companies.
I was very impressed too! For 5 years OGI is my only MJ company with a profit and recreational hasnt even started. I had to add 10,000 to my position
Jumped in!
Very impressive.
NMUS - Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for GlaucomaPress Release | 08/01/2018
https://www.otcmarkets.com/stock/NMUS/news/Nemus-Bioscience-Inc-Signs-Agreement-with-Albany-Molecular-Research-Inc-AMRI-to-Manufacture-Cannabinoid-Based-Active-Pha?id=199624
Organigram Announces Record Q3 Financial Results - Net Income of $2.8 Million for the Quarter
By
Published: July 30, 2018 6:00 a.m. ET
MONCTON, NB, Jul 30, 2018 (Canada NewsWire via COMTEX) -- Growth in production, dried flower sales, oil sales, inventory and the announcement of numerous sales agreements positions Organigram for successful launch of adult recreational use market
Organigram Holdings Inc. (OGI) (otcqb:OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of medical marijuana based in Moncton, New Brunswick, is pleased to announce its financial results for the three and nine-months ended May 31, 2018.
"Our fiscal third quarter was transformational for the Company. Our production capabilities have increased exponentially, we launched our adult recreational brand strategy and have signed agreements with a number of provinces and private retailers as well as announcing key significant investments from both a strategic and international perspective. As we head into the launch of the adult use recreational market we believe Organigram is well positioned to build upon its domestic medical business into becoming a national player in the adult recreational market and a global player in the medical market."
Operational Highlights
-- Organigram began harvesting from its Phase 2 expansion facility (23 grow rooms) on April 20, 2018 bringing its target production of dried flower equivalent to 22,000 kg/annum; -- In May the Company launched its adult recreational brand strategy which included house brands such as The Edison Cannabis Company, ANKR Organics and Trailer Park Buds; -- In May Organigram received a "License for Controlled Drugs and Substances" from Health Canada making the Company a Licensed Dealer; -- In May the Company received its "Permit to Export Cannabis" license which allowed Organigram the ability to make its first international medical shipment to Australia (completed in July); -- Shortly after quarter-end the Company began use of its Phase 3 expansion filling six of the 16 grow rooms with the remaining rooms filled in June and July bringing its target production of dried flower equivalent to 36,000 kg/annum; and -- Announced strategic investments in: Hyasynth Biologicals, Alpha-Cannabis Germany, and Eviana (see previous press releases for more details) which all are expected to close in the calendar third quarter.
Financial Highlights
-- Record net sales for both the three-months and nine-months ended May 31, 2018 of $3.7 million and $10.1 million respectively vs. $1.9 million and $3.6 million respectively for 2017; -- Record sale volume of cannabis oil for the three-months ended May 31, 2018 (768,400 milliliters) up 39% from Q2/18 (552,250) and up 452% from Q3/17 (139,200 milliliters); -- Record sales volume of dried flower (303,428 grams) for the three-months ended up 28% from Q2/18 (237,650 grams) and up 55% from Q3/17 (196,129 grams); -- Record yields per plant in the quarter ended May 31, 2018 (see MD&A for further details); -- Cost of cultivation per gram of dried flower harvested of $0.80 per gram "all-in" (direct labour and materials, allocated overhead and depreciation) and $0.58/gram excluding depreciation. Note that cost of cultivation is a non-GAAP measure used by management internally and does not include indirect production, packaging or shipping costs (see financial statements and MD&A for further details); -- Registered medical patients climbed to a record 15,316 by the end of Q3 up 18% since Q2 (12,957); -- Impairment of goodwill on its 2017 acquisition of Trauma Healing Centres in the amount of $1.2 million related to "right sizing" of the business opportunity; -- Net interest expense of $3.7 million for the quarter primarily attributable to the interest expense on $115 million of convertible debentures issued on January 31, 2018; and -- Net income of $2.8 million, an increase of 162% compared to $1.1 million in Q2-2018 and a loss of $2.3 million in Q3-2017.
Summary of Financial Results
Three-months ended Inc. Nine-months ended Inc May 31 (Decr.) May 31 (Decr.) ------ ------ ------ ------ (in $000 except EPS) 2018 2017 2018 2017 --------------- ---- ---- ---- ---- Gross sales $3,705 $1,917 93% $9,612 $5,593 72% ----------- ------ ------ --- ------ ------ --- Sales recovery (return) $21 $- n/m(1) $490 $(2,026) n/m -------------- --- --- ------ ---- ------- --- Net sales(2) $3,726 $1,917 94% $10,102 $3,567 183% ----------- ------ ------ --- ------- ------ --- Cost of sales (incl. indirect production) $1,671 $2,097 -20% $5,012 $5,905 -15% ---------------- ------ ------ --- ------ ------ --- Gross margin (excluding FV adjustment) $2,055 $(180) n/m $5,090 $(2,338) n/m -------------- ------ ----- --------- ------ ------- --- FV adjust. on bio assets and inventories $10,066 $(578) n/m $15,172 $(1,634) n/m ----------------- ------- ----- --------- ------- ------- --- Gross margin $12,121 $(758) n/m $20,262 $(3,972) n/m ------------ ------- ----- --------- ------- ------- --- General and admin $1,556 $790 97% $4,743 $2,245 111% ----------------- ------ ---- --- ------ ------ --- Sales and marketing $1,754 $691 154% $4,033 $2,063 95% ------------------- ------ ---- --- ------ ------ --- Share-based compensation (non- cash) $1,156 $222 421% $3,056 $787 288% ------------------- ------ ---- --- ------ ---- --- Impairment of goodwill $1,156 $ - n/m $1,156 $ - n/m ------------- ------ ----- --- ------ --- --- Net financing costs (income) (3) $3,679 $(115) n/m $4,778 $(211) n/m ------------------- ------ ----- --- ------ ----- --- Net income (loss) $2,820 $(2,346) n/m $2,496 $(8,856)% ---------------- ------ ------- --- ------ -------- EPS (basic) $0.023 $(0.023) n/m $0.021 $(0.093) n/m ---------- ------ ------- --- ------ ------- --- EPS (diluted) $0.021 $(0.023) n/m $0.019 $(0.093) n/m ------------ ------ ------- --- ------ ------- --- Sales volume of: ---------------- Dried cannabis flower (gr) 303,428 196,129 55% 736,153 598,060 23% -------------- ------- ------- --- ------- ------- --- Cannabis oil sold (ml) 768,400 189,600 305% 1,739,250 406,000 328% ----------------- ------- ------- --- --------- ------- ---
(1) Not meaningful 2 Net sales consist of gross sales and sales recovery (return) and includes dried flower and cannabis oil sales, sales of accessories and revenues from the Company's wholly-owned subsidiary Trauma Healing Center. (3) Net financing costs consist of financing costs less any investment income earned.
Balance Sheet Highlights
At the end of the third-quarter 2018 the Company reported:
-- $156 million in cash and short-term investments (up from $34 million at the August 31, 2017 year-end); -- $26.9 million in combined biological assets and inventories (up from $5.4 million at year-end); -- $83 million in property, plant and equipment (up from $45 million at year-end); -- $9 million in current liabilities (up from $6 million at year-end); -- $98 million in long-term debt and convertible debentures (up from $3 million at year-end); -- 124.6 million outstanding shares (103.5 million at year-end); and -- 140.5 million fully-diluted shares (114.2 million at year-end) - including 7.8 million options (6.3 million at year-end), 8.1 million warrants (4.3 million at year-end), and 21.2 million shares (-Nil at year-end) if the convertible debentures are converted at their conversion price of $5.42.
Outlook
-- Phase 4a (26 grow rooms) and 4b (27 grow rooms) construction expansions began in Q4 including a substantially complete 40-megawatt (peak capacity) substation worth $4 million - total cost of Phases 4a and 4b (including the $4 million spent on the substation) estimated to be $70 million bringing target production capacity to 89,000 kg/annum; -- Phase 4c (24 grow rooms) which has an estimated cost of $40 million would bring target production capacity to 113,000 - construction scheduled to begin in January 2019; -- Organigram expects to close its previously announced investments by the end of the quarter and is looking to augment its domestic and global capabilities with further investments and/or acquisitions; and -- Company is confident it will be able to announce further provincial agreements in the adult recreational market in the current quarter.
For more information, visit www.Organigram.ca
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.
Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company's global footprint. In anticipation of the legal adult use recreational cannabis in Canada, Organigram has developed a portfolio of brands including The Edison Cannabis Company, Ankr Organics and Trailer Park Buds. Organigram's primary facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations ("ACMPR").
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors - including the availability of funds, consummation of definitive documentation, the results of financing efforts, crop yields - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE OrganiGram
View original content with multimedia: http://www.newswire.ca/en/releases/archive/July2018/30/c8086.html
SOURCE: OrganiGram
Just look at Valens. You need to stay away from the stock promotion. Get on a plane and go to Kelowna. Then you'll get it immediately. Execution is everything but this one has a real shot.
Gotta another one for you! Looks interesting....
https://midasletter.com/2018/07/cannabis-extraction-specialist-sproutly-inc-to-make-cse-debut-next-week/
I am "all in" and want to buy more.
Looking for one other MJ play other than Namaste.
I know Valens and the extracts are the place to be as the science gets better. This whole marijuana revolution was started as a result of the Charlotte's web strain and that was really a therapeutic dose based on an extract. Science is rapidly improving in the area of cannabinoid science. As science gathers knowledge, these extracts will become more and more targeted and companies such as Valens will be on the front lines to benefit.
Naturally Splendid Submitted a Dealer License. Not only a hemp play but a growing cannabis play.
Link to press release:
https://ih.advfn.com/p.php?pid=nmona&article=77817447
I am watching Valens Groworks (stock symbol:VGW) very closely. Canadian-based with a real management team trading at less than 5% of the large Canadian cannabis plays. Easier to buy up in Canada under the symbol of VGW. These stocks should move well as we head toward Canadian legalization.
Greenhouse plans announced.
https://www.newswire.ca/news-releases/valens-groworks-finalizes-greenhouse-expansion-plans-686012951.html
Canada lawmakers vote to legalize cannabis
June 18, 2018
The Canadian parliament passed a bill Monday to legalize cannabis that would make Canada the first G7 country to allow free consumption of the mind-altering drug.
The bill was passed by 205 votes to 82 in the House of Commons. The legislation must now pass the Senate, and receive royal assent by the governor general before becoming law, likely by September.
The Senate could still delay its implementation, but not block it.
"We're probably looking at a date of implementation (of legalization) somewhere toward the beginning of September, perhaps mid-September," the Liberal government's pointman on the pot file, Bill Blair, told broadcaster CTV on Sunday.
Last week, the government rejected 13 out of 46 amendments to the bill proposed by the Senate after several months of study, with Prime Minister Justin Trudeau's health minister rising to defend home cultivation of cannabis and branded pot swag.
"Canadians are allowed to make beer at home, or wine," Health Minister Ginette Petitpas Taylor said Friday.
"It is already possible for Canadians to grow cannabis for medical purposes and we absolutely believe the legislation should be consistent when it comes to recreational cannabis."
The government, she said, would follow its expert panel's recommendation to allow at-home cultivation of up to four pot plants for personal use.
As for the proposed advertising restrictions, she said the bill already contains limits such as a requirement for plain packaging.
Legalizing weed was a 2015 campaign promise of Trudeau, who has admitted having smoked a joint with friends "five or six times."
An initial July 1 target was set for ending the pot prohibition that dates back to 1923.
Despite political setbacks, Trudeau has insisted his government would move to legalize the production, sale and consumption of the psychoactive drug this year.
Statistics Canada has estimated that the market will be worth Can$5.7 billion ($4.5 billion US), based on last year's consumption data.
Like a Hurricane: Liberty Plans to
Take Florida by Storm
June 5, 2018
Coverage: Clarus Securities Inc.
https://libertyhealthsciences.com/wp-content/uploads/2018/06/Clarus-Securities-Report-on-Liberty-Health-Sciences.pdf
Good read on liberty and state of FL market.
LHSIF
Thursday.
C-45 for Canada
When are the votes dO?
$TGIF set to rocket? http://thecse.com/en/listings/diversified-industries/friday-night-inc
MedMen, Largest U.S. Cannabis Company, Begins Trading on the Canadian Securities Exchange May 29th Under Ticker Symbol "MMEN"
Leading Cultivator, Producer and Retailer of State-Sanctioned Cannabis, now Accessible to Public Equity Investors
Los Angeles (May 29, 2018) - MedMen Enterprises Inc. will begin trading today on the Canadian Securities Exchange ("CSE") under the ticker symbol "MMEN" at 11 a.m. EDT.
With more than 800 employees and 18 licensed facilities in California, Nevada and New York, MedMen is one of the fastest growing companies in the quickly evolving U.S. cannabis industry. The three states where MedMen currently operates account for about half of the addressable cannabis market in the U.S. State-sanctioned cannabis sales in the country are estimated at about US$ 7 billion annually and expected to reach US$ 75 billion by 2030, according to the Cowen Group.
"MedMen's vision is simple but revolutionary: cannabis as a consumer product," said MedMen Co-founder and CEO Adam Bierman. "For the better part of a decade we have been singularly focused on that vision - creating the systems and infrastructure that raise the bar on product quality and safety and providing a retail shopping experience that is second to none. By going public, MedMen gives investors a ground-floor opportunity to participate in the enormous and untapped potential of the fastest growing industry in the United States."
The listing follows the successful completion of a reverse takeover of a Canadian public company by U.S.-based MM Enterprises USA, LLC. In connection with this reverse takeover and the listing on the CSE, the Company raised approximately CA$ 143 million, or US$ 110 million, through a private placement at an implied enterprise valuation of CA$ 2.14 billion, or US$ 1.65 billion. Executives of MM Enterprises USA, LLC were appointed as officers of the public company and the public company was renamed MedMen Enterprises Inc.
"We are making marijuana mainstream by making it okay for soccer moms and middle-aged professionals to use cannabis products," said MedMen Co-founder and President Andrew Modlin, the creative force behind MedMen and the first cannabis professional to win the prestigious American Marketing Association's Emerging Leaders Award. "People are using it for ailments, for wellness or to just relax or socialize with friends. Medical marijuana is legal in 29 states, adult use is now legal in nine. Medical use is legal in Canada and adult use is expected to be legal by year's end. We are marching steadily toward a future where buying and using cannabis products will be just as normal as buying wine or beer."
It is common for U.S.-based cannabis businesses to trade on the over-the-counter ("OTC") market. In recent years, a growing number of American marijuana companies have sought a listing on the CSE, a more reputable, bona fide global exchange. Canada-based marijuana companies like the Cronos Group and Canopy Growth have listed on major U.S. exchanges recently, but U.S. marijuana companies are barred from listing on the NYSE or Nasdaq. The CSE gives American cannabis companies broader exposure to a global investor audience. Cassels Brock & Blackwell LLP acted as counsel to MedMen in connection with the financing and the listing on the CSE. MedMen engaged Cormark Securities Inc. and Canaccord Genuity Corp. to act as co-bookrunners on behalf of a syndicate of agents to complete the financing.
"Our listing on the CSE will give MedMen greater flexibility in accessing capital in the public equity markets to leverage our first-mover advantage and to build upon our track record of growth," Bierman said. "At the same time, it will provide global investors an opportunity to invest in the preeminent cannabis company in the U.S. for the first time ever."
One of the Most Recognized Brands in the Industry
Nine premium stores in the U.S. feature MedMen's award-winning retail concept, including its flagship store on New York City's Fifth Avenue, which opened last month. MedMen is licensed to operate a total of four stores in New York State, all of which are currently operational, and the Company plans to upgrade its three other New York stores to align with its distinctive retail brand. The Company also continues to explore and acquire prime real estate in upscale retail districts in strategic markets across North America. MedMen recently signed a joint venture agreement with Cronos Group to explore opening MedMen branded and managed stores in Canada once adult-use is legalized.
Industry Leading Cultivation and Production Facilities
MedMen operates scalable, highly-efficient cultivation facilities using the latest in agronomic technology and sustainable techniques, and its manufacturing facilities use standards comparable to those in the biotech and pharmaceutical industries. MedMen owns and operates two cultivation and production facilities, one in Nevada and the other in New York. The Company is currently developing additional large-scale cultivation and production operations in California and New York and a genetics facility in Nevada, while also expanding the cultivation area of its existing Nevada facility. Management intends to establish a strong foothold in these states as they offer high-growth potential due to their market depth, supply-demand dynamics and regulatory framework.
About MedMen
MedMen Enterprises is the preeminent cannabis company in the United States with multiple assets and operations in California, Nevada and New York, which combined account for nearly half of North America's addressable legal market. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is one of the most well recognized cannabis brands in the world today. Headquartered in Los Angeles, MedMen Enterprises employs more than 800 people across the United States.
The predecessor to MedMen Enterprises was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society's relationship with cannabis. MedMen supports sensible, clear and just drug laws. The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates.
For more information, visit http://www.medmen.com or follow us on Facebook, Twitter or Instagram.
Concurrent with the public listing, the Company will launch its new investor relations website at investors.medmen.com.
A listing statement describing MedMen Enterprises and prepared in accordance with the policies of the CSE will be available on SEDAR at www.sedar.com.
For further information, please contact:
Media Contact:
Daniel Yi
Senior Vice President of Corporate Communications, MedMen Enterprises
E-mail: daniel@medmen.com
Investor Relations Contact:
Stéphanie Van Hassel
Head of Investor Relations, MedMen Enterprises
Email: investors@medmen.com
At 9:00AM CENTRAL tomorrow.
Followers
|
32
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
658
|
Created
|
01/06/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |